

# **US INFECTIOUS DISEASE TESTING MARKET**

## **Table of Contents**

### **Introduction**

### **Worldwide Market and Technology Overview**

#### **A. Major Infectious Disease Tests**

##### **1. AIDS**

###### **a. Background**

- **Structure and Composition**
- **Classification**
- **Origin of AIDS**
- **Animal Lentivirus Systems**
- **Virus Receptors**
- **HIV Infections in Humans**
  - **Pathogenesis & Pathology: Overview of HIV Infection Course**
- **CD4<sup>T</sup> Lymphocytes and Memory Cells**
- **Monocytes and Macrophages**
- **Lymphoid Organs**
- **Neural Cells**
- **Viral Coinfections**
  - **Clinical Findings**
- **Plasma Viral Load**
- **Pediatric AIDS**
  - **Neurologic Disease**
  - **Opportunistic Infections**
  - **Cancer**
- **Immunity**
  - **Virus Isolation**
  - **Serology**
  - **Detection of Viral Nucleic Acid and Antigens**
- **Infectivity**
- **Epidemiology**
  - **Worldwide Spread of AIDS**
  - **United States**
  - **Routes of Transmission**

Table of Contents (continued)

- b. Diagnostic Tests**
    - **Laboratory Diagnosis**
      - **Enzyme Immunoassay Interpretation**
      - **Specific, Sensitivity, and Predictive Value of Enzyme Immunoassays**
    - **Competition Assays**
    - **Western Blot Technique**
    - **Immuno-Fluorescence Assay (IFA)**
    - **Radioimmunoprecipitation**
    - **HIV-1/HIV-2 Combination Testing**
    - **Methods of HIV-Antigen Detection**
    - **Antigen Assays and Blood Screening**
    - **Urine Tests**
    - **Immunopathogenic Mechanism of HIV Infection**
    - **DNA Probes**
      - **Overview**
      - **Quantitative Polymerase Chain Reaction**
      - **In Situ PCR**
      - **Needed Improvements**
    - **Viral Load/Drug Resistance Testing**
    - **Genotype and Phenotype Testing**
    - **Blood Banking Consideration**
  - c. Vaccines and Drugs**
    - **Antiviral Drugs**
    - **Vaccines Against HIV**
    - **Transmission of HIV in Blood Products**
    - **HIV Transmission in Transplant and Artificial Insemination Recipients**
- 2. Adenovirus**
- a. Background**
  - b. Diagnostic Tests**
  - c. Vaccines and Drugs**
  - d. Adeno-Associated Viruses(AAV)**
- 3. Aeromonas**
- a. Background**
  - b. Diagnostic Tests**
  - c. Vaccines and Drugs**
- 4. Anthrax/Bacillus Anthracis**
- a. Background**



Table of Contents (continued)

- *Chlamydia Pneumoniae*
    - *Chlamydia Trachomatis*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 15. *Clostridium Difficile*
  - a. *Background*
    - *Pediatric Infections*
    - *Epidemiology*
  - b. *Diagnostic Tests*
    - *Counterimmunoelectrophoresis*
    - *Fluorescent-Antibody Assays*
    - *Polymerase Chain Reactions*
  - c. *Drugs and Vaccines*
- 16. *Coronaviruses*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 17. *Coxsackieviruses*
  - a. *Background*
    - *Herpangina*
    - *Hand-foot-and-mouth syndrome*
    - *Epidemic Conjunctivitis*
    - *Pharyngitis*
    - *Epidemic Pleurodynia*
    - *Myocarditis, Pericarditis*
    - *Overwhelming Infection of the Newborn*
    - *Acute Aseptic Meningitis*
    - *Undifferentiated Febrile Illness*
    - *Fever with upper respiratory infection*
    - *Encephalitis*
    - *Asymptomatic Infection*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 18. *Creutzfeldt-Jakob's Disease*
  - a. *Background*
    - *Blood Transmission*
  - b. *Diagnostic Tests*
    - *Major Commercial and Academic Players*
      - *Bayer*

Table of Contents (continued)

- Disease Sciences/Bio Tec Global
- Imperial College of Medicine
- Ortho-Clinical Diagnostics
- Pall
- ProMetic Life Sciences
- Proteome Sciences/Idexx
- Q-One Biotech
- Serono
- U.S. Agricultural Research Service
- c. Vaccines
- 19. *Cryptosporidium Parvum*
  - a. Background
  - b. Diagnostic Tests
    - o Histologic
    - o Laboratory Parasitology
    - o Serodiagnosis
  - c. Vaccines and Drugs
- 20. *Cyclospora Cayetanensis*
  - a. Background
    - o Asymptomatic Infection
    - o Diarrhea in Immunocompetent Persons
    - o Diarrhea in Immunocompromised persons
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 21. *Cytomegalovirus*
  - a. Background
    - o Chorioretinitis
    - o Gastrointestinal
    - o Central Nervous System Disease
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 22. *Ebola Virus*
  - a. Background
    - o Epidemiology
    - o Hemorrhagic Fever
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 23. *E. Coli*
  - a. Background

Table of Contents (continued)

- *Role of Escherichia Coli in Causing Diarrhea*
- *EPEC*
- *ETEC*
- *EIEC*
- *EHEC*
- b. Diagnostic Tests*
- c. Vaccines and Drugs*
- 24. *EchoVirus*
  - a. Background*
    - *Acute Aseptic Meningitis*
    - *Encephalitis*
    - *Exanthems*
    - *Respiratory Disease*
    - *Myope;ricarditis*
    - *Neonatal Infections*
  - b. Diagnostic Tests*
  - c. Vaccines and Drugs*
- 25. *Encephalitis*
  - a. Background*
  - b. Diagnostic Tests*
  - c. Vaccines and Drugs*
- 26. *Enteroviruses*
  - a. Background*
  - b. Diagnostic Tests*
    - *Viral Isolation and Identification*
    - *Antibody Tests*
  - c. Vaccines and Drugs*
- 27. *Epstein-Barr Virus*
  - a. Background*
  - b. Diagnostic Tests*
  - c. Vaccines and Drugs*
- 28. *Giardia Lamblia*
  - a. Background*
    - *Life Cycle and Morphology*
    - *Morphology of Trophozoites*
    - *Clinical Disease*
  - b. Diagnostic Tests*
  - c. Vaccines and Drugs*

Table of Contents (continued)

- 29. *Gonorrhoea*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 30. *Granuloma Inguinale*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 31. *Hantavirus*
  - a. *Background*
    - o *Identification of the Agent*
    - o *Transmission*
    - o *Other Rodent Hantaviruses*
    - o *Distribution*
    - o *Hantavirus Diseases*
    - o *Epidemiology*
    - o *Addendum in Proof-Northeastern Connection*
    - o *Previously Unknown Pathogens*
    - o *Cases Nationwide*
  - b. *Diagnostic Tests*
    - o *An Immunohistochemistry Approach*
    - o *Hantavirus Rapid Diagnostic Test*
    - o *ELISA Diagnosis of Hantavirus Pulmonary Syndrome*
    - o *IgG ELISA*
    - o *IgM Capture ELISA*
  - c. *Vaccines and Drugs*
- 32. *Helicobacter Pylori*
  - a. *Background*
    - o *Pathogenesis*
    - o *Role in Peptic Ulcer Disease*
    - o *Role in Gastric Cancer*
    - o *Nonulcer Dyspepsia*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
    - o *Specific Therapeutic Regimens*
    - o *Who Should Be Treated?*
    - o *Participants in Controlled Clinical Trials*

Table of Contents (continued)

- *Patients with Refractory Peptic Ulcer*
- *Patients with Refractory NUD*
- *Patients in High-Risk Groups for Gastric Cancer*
- 33. Hepatitis**
  - a. Background**
  - b. Hepatitis A**
  - c. Hepatitis B**
  - d. Hepatitis C**
    - *Classification*
    - *Transmission of Infection*
    - *Occupational Hazards*
    - *Acute Hepatitis*
    - *Diagnosis of Acute Infection*
    - *Chronic Hepatitis*
    - *HCV and Other Chronic Liver Diseases*
    - *Alcoholic Liver Disease*
    - *Hepatitis B Coinfection*
    - *Cirrhosis and Hepatocellular Carcinoma*
    - *Diagnostic Tests*
    - *Possible Indications for HCV RNA Testing*
    - *Conclusions and Future Direction*
  - e. Hepatitis D**
    - *Historical Perspective*
    - *Epidemiology*
    - *HBV-HDV "Coinfection" vs. "Superinfection"*
    - *Methods of Detecting HDV*
    - *Prevention*
  - f. Hepatitis E**
    - *Background*
    - *Prevalence of the Disease*
    - *Diagnostic Tests*
    - *Epidemiologic Serosurveys*
    - *Serologic Cross-Reactivity*
  - g. Hepatitis G**
    - *Vaccines and Drugs*
- 34. Herpes Simplex Virus**
  - a. Background**
  - b. Diagnostic Tests**
  - c. Vaccines and Drugs**

Table of Contents (continued)

- 35. *Human Herpes Virus-6 (HHV-6)*
  - a. *Background*
    - *HIV-6 Infections*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 36. *Influenza Viruses*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 37. *Legionella*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 38. *Lyme Disease*
  - a. *Background*
    - *Clinical Description*
    - *Clinical Case Definition*
    - *Laboratory Criteria for Diagnosis*
    - *Case Classification*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 39. *Lymphogranuloma Venereum (LGV)*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 40. *Malaria*
  - a. *Background*
  - b. *Diagnostic Tests*
    - *Potential Diagnostic Problems with Positive Patients from Non-endemic Areas*
      - *Patient*
      - *Laboratory*
      - *Physician*
  - c. *Vaccines and Drugs*
- 41. *Measles (Rubeola)*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*

Table of Contents (continued)

**42. Meningitis**

**a. Background**

**b. Diagnostic Tests**

**c. Vaccines and Drugs**

- *Development of Polysaccharide Vaccines*
- *Quadrivalent Vaccine Development*
- *Meningococcal A.C.Y. & W-135 Vaccines*
- *Efficacy of Group C Vaccine*
- *Efficacy of Group A Vaccine*
- *Combinations of Group A and C Vaccines*
- *Group B Efficacy Trials*
- *Future Direction*

**43. Microsporidium**

**a. Background**

- *Prevalence and Geographic Distribution*
- *Sources of Human Infection and Transmission*

**b. Diagnostic Tests**

- *Light Microscopic Examination of Stool Specimens By Chromotrope Staining*
- *Stool Concentration Methods*
- *Chemofluorescent Agents*
- *Giemsa Staining of Stool Specimens*
- *Cytologic Diagnosis*
- *Histologic Examination*
- *Electron Microscopy*
- *Examination of Bodily Fluids*
- *Examination of Tissue Sections*
- *Immunofluorescence Detection Procedures*
- *Serology*
- *Cell Culture*
- *Approach to Diagnosis*
- *Evaluation of Patients with Presumptive Intestinal Microsporidiosis*
- *Evaluation of Patients with Presumptive Ocular Microsporidiosis*

**c. Vaccines and Drugs**

**44. Mononucleosis**

**a. Background**

**b. Diagnostic Tests**

**c. Vaccines and Drugs**

Table of Contents (continued)

- 45. *Mumps*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
    - *Efficacy of Vaccination*
    - *Future Issues*
- 46. *Mycoplasma*
  - a. *Background*
    - *Ureaplasma Urealyticum & Mycoplasma Hominis*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 47. *Papillomaviruses*
  - a. *Background*
    - *HPV in Cancer*
    - *Cervical Neoplasm*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
    - *Prevention*
- 48. *Parvovirus B19*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 49. *Pneumonia*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 50. *Polyomaviruses*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 51. *Pseudomonas Aeruginosa*
  - a. *Background*
    - *Virulence Factors*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 52. *Rabies*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*

Table of Contents (continued)

- 53. *Respiratory Syncytial Virus (RSV)*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 54. *RhinoViruses*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 55. *RotaVirus (REOVIRUS)*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 56. *Rubella(MEASLES)*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
    - *Developing Countries*
    - *Elimination and Eradication of Measles*
    - *New Developments*
- 57. *Salmonellosis*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 58. *Septicemia*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 59. *Shigellosis*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- 60. *Staphylococcus Aureus*
  - a. *Background*
    - *The Genus Taphylococcus*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
    - *Prevention*
- 61. *Streptococci*
  - a. *Background*
  - b. *Diagnostic Tests*



Table of Contents (continued)

- 68. *Yersina*
  - a. *Background*
  - b. *Diagnostic Tests*
  - c. *Vaccines and Drugs*
- B. *Instrumentation Review and Market Needs*
  - o *Abbott AxSYM*
  - o *Abbott IMx/IMx Select*
  - o *Anagen AN2000/AuraFlex*
  - o *Siemens Immuno 1*
  - o *Beckman Coulter Access*
  - o *BioChem Pharma/SR1*
  - o *BioMerieux/Vitek Vidas*
  - o *Biotrol System 7000*
  - o *Chiron ACS: Centaur*
  - o *Chiron ACS: 180*
  - o *Siemens ELISA Processor II/III*
  - o *Siemens/Opus/Plus/Magnum*
  - o *Siemens Stratus*
  - o *J&J Diagnostics Vitros Eci*
  - o *J&J Diagnostics/Amersham Amerlite*
  - o *Olympus PK310*
  - o *Roche Elecsys 1010/2010*
  - o *Roche Cobas Core*
  - o *Roche ES 300/300AL*
  - o *Roche ES 22*
  - o *Roche ES 33*
  - o *Tosoh AIA-1200/1200DX/NexIA/600*
  - o *Wallac/Pharmacia Delfia*
- C. *Emerging Diagnostic Technologies*
  - 1. *DNA Probes*
    - a. *Technology Overview*
    - b. *Amplification Methods*
      - o *Polymerase Chain Reaction*
        - *Robotics*
        - *Temperature Cyclers*
        - *PCR Variations*
      - o *Immuno-PCR*
      - o *QC-PCR*
      - o *DAP-PCR*

Table of Contents (continued)

- *Ligase Chain Reaction*
- *Branched DNA*
- *Q-Beta Replicase*
- *Nucleic-Acid Sequence-Based*
- *Strand Displacement Activation*
- *Self-Sustained Sequence Replicase*
- 2. *Monoclonal Antibodies*
- 3. *Immunoassays*
  - a. *Technological Principle*
  - b. *Enzyme Immunoassays (EIA)*
    - *Overview*
    - *ELISA*
    - *Dot Immunobinding Assays*
    - *Capillary Immunoassays*
    - *Particle-Membrane Capture*
    - Immunoassays*
      - *Enzyme Amplification*
  - c. *Fluorescent Immunoassays*
    - *Fluorescence Polarization*
    - *Time-Resolved Pulse Fluorescence*
  - d. *Luminescence*
    - *Chemiluminescence*
    - *Bioluminescence*
  - e. *Latex Agglutination*
  - f. *Immunoprecipitation*
- 4. *Differential Light Scattering*
- 5. *Microcomputers and Automation*
- 6. *Artificial Intelligence*
- 7. *Liposomes*
- 8. *Flow Cytometry*
- 9. *Chromatography*
- 10. *MRI*
- 11. *Gel Microdroplets*
- 12. *Other*
- D. *Personal Testing*
- E. *Worldwide Business Environment*
- F. *Worldwide Market Structure*
- G. *Worldwide Market Size and Growth*

Table of Contents (continued)

U.S.A.

- A. *Executive Summary*
- B. *Business Environment*
  - 1. *Health Care Expenditures*
  - 2. *Cost Consciousness*
  - 3. *Reimbursement*
  - 4. *Industry Consolidation*
  - 5. *Managed Care*
    - a. *HMO*
    - b. *PPO*
  - 6. *Hospitals*
  - 7. *Admissions*
  - 8. *Length of Stay*
  - 9. *Industry Diversification*
  - 10. *Physician Demographics*
  - 11. *Population Aging*
    - a. *Chronic Illness*
    - b. *Disease Incidence*
    - c. *Susceptibility to Iatrogenesis*
    - d. *Multiple Illness Cases*
  - 12. *Laboratory Regulations*
  - 13. *FDA Reform*
- C. *Market Structure*
  - 1. *Centralized Testing*
    - a. *Hospitals*
    - b. *Commercial/Private Laboratories*
    - c. *Blood Banks*
      - 1) *Community and Regional Centers*
      - 2) *Plasma Fractionation Centers*
  - 2. *Decentralized Testing*
    - a. *Physician Offices/Group Practices*
    - b. *Point of Care Testing*
    - c. *Other Decentralized Testing Locations*
- D. *Market Size, Growth and Major Suppliers*

Table of Contents (continued)

Major Product Development Opportunities

- A. Instrumentation
- B. Reagent Kits and Test Systems/Panels
- C. Computers, Software and Automation
- D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies for Decentralized Testing Markets
  - 1. Marketing Approaches
  - 2. Product Complexity
  - 3. Customer Preference
  - 4. Established Suppliers
  - 5. Emerging Suppliers
  - 6. Major Types of Distributors
  - 7. Market Segmentation

Potential Market Entry Barriers and Risks

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

Competitive Assessments

- Abbott
- Affymetrix
- Applera

Table of Contents (continued)

- Beckman Coulter
- Becton Dickinson
- Binding Site
- Biomerica
- Biokit
- bioMerieux
- Bio-Rad
- Biotrol
- Biosite
- Biotest
- Caliper Technologies
- Cepheid
- Chemicon
- Daiichi
- DiaSorin
- Diagast
- Diamedix
- Digene
- Eiken
- Enzo Biochem
- Fujirebio
- GenBio
- Gene-Tec
- Hemagen
- Immunetics
- Innogenetics
- Inverness
- J&J
- Meridian
- Nanogen
- Nissui
- Olympus
- Provalis
- Roche
- Saliva Diagnostic
- SeraCare
- Siemens
- Third Wave Technologies

Table of Contents (continued)

- *Thermo Fisher*
- *Tosho*
- *Trinity Biotech*
- *Tropix*
- *Wampole Labs*
- *Zenith*
- *Zeus*

Appendix: *Assumed Currency Exchange Rates*

List of Tables

*Major Companies Developing or Marketing AIDS Tests*

*Major Companies Developing or Marketing Adenovirus Tests*

*Major Companies Developing or Marketing Bartonella Tests*

*Major Companies Developing or Marketing Campylobacter Tests*

*Major Companies Developing or Marketing Candida Tests*

*Major Companies Developing or Marketing Chlamydia Tests*

*Major Companies Developing or Marketing Clostridium Tests*

*Major Companies Developing or Marketing Coronavirus Tests*

*Major Companies Developing or Marketing Cryptosporidium Tests*

*Major Companies Developing or Marketing CMV Tests*

*Major Companies Developing or Marketing Echovirus Tests*

*Major Companies Developing or Marketing Enterovirus Tests*

*Major Companies Developing or Marketing EBV Tests*

List of Tables (continued)

*Major Companies Developing or Marketing Giardia Tests*

*Major Companies Developing or Marketing Gonorrhea Tests*

*Major Companies Developing or Marketing Hantavirus Tests*

*Major Companies Developing or Marketing Helicobacter Pylori Tests*

*Major Companies Developing or Marketing Hepatitis Tests*

*Major Companies Developing or Marketing Herpes Tests*

*Major Companies Developing or Marketing Influenza Tests*

*Major Companies Developing or Marketing Legionella Tests*

*Major Companies Developing or Marketing Lyme Disease Tests*

*Major Companies Developing or Marketing Lymphogranuloma Tests*

*Major Companies Developing or Marketing Malaria Tests*

*Major Companies Developing or Marketing Measles Tests*

*Major Companies Developing or Marketing Meningitis Tests*

List of Tables (continued)

*Major Companies Developing or Marketing Microsporidium Tests*

*Major Companies Developing or Marketing Mononucleosis Tests*

*Major Companies Developing or Marketing Mumps Tests*

*Major Companies Developing or Marketing Mycoplasma Tests*

*Major Companies Developing or Marketing Papilloma Virus Tests*

*Major Companies Developing or Marketing Parvovirus Tests*

*Major Companies Developing or Marketing Pneumonia Tests*

*Major Companies Developing or Marketing RSV Tests*

*Major Companies Developing or Marketing Rotavirus Tests*

*Major Companies Developing or Marketing Rubella Tests*

*Major Companies Developing or Marketing Salmonella Tests*

*Major Companies Developing or Marketing Septicemia Tests*

*Major Companies Developing or Marketing Shigella Tests*

*Major Companies Developing or Marketing Staphylococci Tests*

List of Tables (continued)

*Major Companies Developing or Marketing  
Streptococci Tests*

*Major Companies Developing or Marketing Syphilis  
Tests*

*Major Companies Developing or Marketing Toxoplasmosis  
Tests*

*Major Companies Developing or Marketing Trichomonas  
Tests*

*Major Companies Developing or Marketing Tuberculosis  
Tests*

*Major Companies Developing or Marketing West Nile  
Tests*

*Major Companies Developing or Marketing Yersinia Tests*

*Worldwide All Market Segments Laboratories  
Performing Infectious Disease Tests by  
Country*

*Worldwide All Market Segments Total Infectious  
Disease Test Volume Forecast by Country*

*Worldwide All Market Segments Total Infectious  
Disease Diagnostics Market Forecast by Country*

*Infectious Disease Tests Major Issues and Market  
Potential For Personal Testing*

*U.S.A. Summary Table  
All Infectious Diseases Test Volume and Diagnostics  
Sales Forecast by Market Segment*

*U.S.A.  
Laboratories Performing Infectious Disease Tests  
by Market Segment*

List of Tables (continued)

U.S.A.

*Hospital Laboratories Performing Infectious Disease Tests by Bed Size*

U.S.A.

*Commercial/Private Laboratories Performing Infectious Disease Tests by Annual Test Volume*

U.S.A.

*Physician Office Laboratories Performing Infectious Disease Tests by Practice Size*

U.S.A.

*All Market Segments Infectious Disease Test Volume Forecast*

U.S.A.

*Hospital Laboratories Infectious Disease Test Volume Forecast*

U.S.A.

*Blood Banks Infectious Disease Test Volume Forecast*

U.S.A.

*Physician Office Laboratories Infectious Disease Test Volume Forecast*

U.S.A.

*Commercial/Private Laboratories Infectious Disease Test Volume Forecast*

U.S.A.

*Public Health Laboratories Infectious Disease Test Volume Forecast*

U.S.A.

*All Market Segments Infectious Disease Diagnostics Market Forecast*

List of Tables (continued)

U.S.A.

*Hospital Laboratories Infectious Disease Diagnostics  
Market Forecast*

U.S.A.

*Blood Banks Infectious Disease Diagnostics Market Forecast*

U.S.A.

*Physician Office Laboratories Infectious Disease  
Diagnostics Market Forecast*

U.S.A.

*Commercial/Private Laboratories Infectious Disease  
Diagnostics Market Forecast*

U.S.A.

*Public Health Laboratories Infectious Disease  
Diagnostics Market Forecast*

U.S.A.

*HIV or HIVI/hIVII Test Volume and Diagnostics Sales  
Forecast by Market Segment*

U.S.A.

*HTLV I or HTLV I/HTLV II Test Volume and Diagnostics  
Sales Forecast by Market Segment*

U.S.A.

*HIVAg Test Volume and Diagnostics Sales Forecast by Market  
Segment*

U.S.A.

*Western Blot/Other Confirmatory Test Volume and  
Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Adenovirus Test Volume and Diagnostics Sales Forecast by  
Market Segment*

List of Tables (continued)

U.S.A.

*Aeromonads Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*BEA Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Blastocystis Hominis Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Campylobacter Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Candida Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Chancroid Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Chlamydia Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Clostridium Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Coronavirus Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Cryptosporidium Test Volume and Diagnostics Sales Forecast by Market Segment*

List of Tables (continued)

U.S.A.

*CMV Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*E. Coli Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Echovirus Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Enterovirus Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*EBV Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Giardia Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Gonorrhoea Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Granuloma Inguinale Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Hantavirus Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Helicobacter Pylori Test Volume and Diagnostics Sales Forecast by Market Segment*

List of Tables (continued)

U.S.A.

HBSAg

Test Volume and Diagnostics Sales Forecast by Market Segment

U.S.A.

Hepatitis C Test Volume and Diagnostics Sales Forecast by  
Market Segment

U.S.A.

Anti-HBC Test Volume and Diagnostics Sales Forecast by  
Market Segment

U.S.A.

Anti-HBS Test Volume and Diagnostics Sales Forecast by  
Market Segment

U.S.A.

Anti-HAV Test Volume and Diagnostics Sales Forecast by  
Market Segment

U.S.A.

Hepatitis Delta Test Volume and Diagnostics Sales  
Forecast by Market Segment

U.S.A.

HBcAg Test Volume and Diagnostics Sales Forecast by  
Market Segment

U.S.A.

HBeAg Test Volume and Diagnostics Sales Forecast by Market  
Segment

U.S.A.

ALT/SGPT Test Volume and Diagnostics Sales Forecast by  
Market Segment

U.S.A.

Herpes Simplex I and II Test Volume and Diagnostics  
Sales Forecast by Market Segment

List of Tables (continued)

U.S.A.

*Herpes Type VI Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Influenza Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Legionella Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Lyme Disease Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Lymphogranuloma Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Malaria Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Measles Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Meningitis Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Microsporidium Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Mononucleosis Test Volume and Diagnostics Sales Forecast by Market Segment*

List of Tables (continued)

U.S.A.

*Mumps Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Mycoplasma Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Papilloma Virus Test Volume and Diagnostics Sales Forecast by Market Segment*

U.s.a.

*Parvovirus Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Pneumonia Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Poliomaviruses Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Pseudomonas Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Rabies Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Rsv Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Rheumatoid Arthritis Test Volume And Diagnostics Sales Forecast by Market Segment*

List of Tables (continued)

U.S.A.

*Rhinovirus Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Rotavirus Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Rubella Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Salmonella Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Scleroderma Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Septicemia Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Shigella Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Staphylococci Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Streptococci Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Syphilis Test Volume and Diagnostics Sales Forecast by Market Segment*

List of Tables (continued)

U.S.A.

*Toxoplasmosis Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Trichomonas Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Tuberculosis Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Vibrio Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*Yersinia Test Volume and Diagnostics Sales Forecast by Market Segment*

U.S.A.

*AIDS Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Western Blot Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Adenovirus Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Campylobacter Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Candida Testing Market Diagnostics Sales by Major Supplier*

List of Tables (continued)

U.S.A.

*Chancroid Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Chlamydia Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*CMV Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Echovirus Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Enterovirus Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*EBV Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Gonorrhoea Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Hepatitis Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Hepatitis C Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Herpes Testing Market Diagnostics Sales by Major Supplier*

List of Tables (continued)

U.S.A.

*Influenza Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Legionella Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Lyme Disease Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Measles Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Meningitis Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Mononucleosis Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Mumps Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Mycoplasma Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Papilloma Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Pneumonia Testing Market Diagnostics Sales by Major Supplier*

List of Tables (continued)

U.S.A.

*Rabies Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*RSV Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Rheumatoid Arthritis Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Rotavirus Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Rubella Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Salmonella Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Septicemia Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Shigella Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Streptococci Testing Market Diagnostics Sales by Major Supplier*

U.S.A.

*Syphilis Testing Market Diagnostics Sales by Major Supplier*

List of Tables (continued)

U.S.A.

*Toxoplasmosis Testing Market Diagnostics Sales by  
Major Supplier*

U.S.A.

*Trichomonas Testing Market Diagnostics Sales by  
Major Supplier*

U.S.A.

*Tuberculosis Testing Market Diagnostics Sales by  
Major Supplier*

U.S.A.

*Infectious Disease Diagnostic Testing Instrumentation  
Major Systems Estimated Placements and Installed Base*